JPRN-UMIN000008966已完成2 期
The study of efficacy and safety of palonosetron for high-risk chemotherapy induced nausea and vomiting in malignant lymphoma. - The study of efficacy and safety of palonosetron for high-risk chemotherapy induced nausea and vomiting in malignant lymphoma.
Shimane University Hospital,cancer center0 个研究点目标入组 54 人开始时间: 2012年9月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patient has severe complication require treatment. 2)Patient has more than CTCAE grade1 nausea and vomiting before chemotherapy. 3)Patient has hypersensitivity of Palonosetron or the other 5-HT3 antagonist. 4)Pregnant or nursing women. Patient refuses to contraception. 5)Patient is deemed inappropriate by doctors.
研究者
相似试验
尚未招募
不适用
Comparison of Palonosetron with Palonosetron and Dexamethasone in avaoiding Post-Operative Nausea and Vomiting in Female Patients Undergoing Laparoscopy surgeryCTRI/2019/09/021070SPS Hospitals
已完成
不适用
The effect of Palonosetron for the prevention of postoperative nausea and vomitingKCT0000581Soon Chun Hyang University Hospital Seoul214
已完成
不适用
Efficacy of palonosetron plus aprepitant in preventing chemoradiotherapy-induced nausea and emesis in patients receiving daily low-dose cisplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a phase II studycervical cancerJPRN-UMIN000011616Chiba University Hospital20
已完成
2 期
Intravenous Palonosetron With Radiotherapy and Concomitant TemozolomideMalignant GliomaNCT00900757Duke University57
已完成
3 期
A randomized phase III trial of palonosetron versus palonosetron plus dexamethasone (day1) for the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy (HOPE-02)Colorectal CancerJPRN-UMIN000013249HOPE group(Hokkaido Supportive Care Oncology Project - an Expert Group Initiative)320